文献速递甲状腺核医学核素与放射性配体治疗

分化型甲状腺癌患者基于疗效评估的放射性碘治疗临床病理危险因素:多中心回顾性队列研究

Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-12-10

该多中心回顾性队列纳入25家医院1563例分化型甲状腺癌患者,比较两种随访方案和两种疗效分类下预测因素的差异。加做放射性碘扫描后卓越缓解比例从76.5%降至59.6%(P<0.001)。高剂量放射性碘(3.7 GBq或更高)在两种方案和两种分类下均显著预测良好疗效。

要点

  • 加做放射性碘扫描后卓越缓解比例从76.5%降至59.6%(P<0.001)。
  • 重组人TSH准备在含放射性碘扫描评估时预测卓越缓解(OR 2.129;95%CI 1.687-2.685;P<0.001)。
  • 高剂量放射性碘(3.7 GBq或更高)在两种方案和两种分类下均显著预测良好疗效。

核心结论

  • 与疗效预测相关的因素的临床影响因随访方案或疗效标准分类不同而异。
  • 无论随访方案或疗效标准分类如何,高剂量放射性碘治疗均是预测良好疗效的显著因素。

研究设计与样本

  • 多中心回顾性队列研究,从25家医院回顾性纳入1563例全甲状腺切除或近全切除后首次接受放射性碘治疗的分化型甲状腺癌患者。
  • 疗效评估采用两种方案:血清甲状腺球蛋白(Tg)联合颈部超声,以及血清Tg、颈部超声联合放射性碘扫描;疗效分类为卓越与非卓越或可接受与不可接受。
  • 采用多因素逻辑回归分析确定显著预测疗效的因素。

主要发现

  • 加做放射性碘扫描后卓越缓解组比例从76.5%显著降至59.6%(P<0.001)。
  • 准备方法(重组人TSH vs 甲状腺激素撤退)在含放射性碘扫描评估的卓越缓解预测中为显著因素(OR 2.129;95%CI 1.687-2.685;P<0.001),在其他类型疗效分类中不显著。
  • 给予的放射性碘活度分为低(1.11 GBq)或高(3.7 GBq或更高),无论随访方案如何均显著预测卓越和可接受缓解。

关键数值与推荐

  • 卓越缓解比例:加做放射性碘扫描前76.5%,加做后59.6%(P<0.001)。
  • 准备方法预测卓越缓解(含放射性碘扫描评估):OR 2.129(95%CI 1.687-2.685;P<0.001)。
  • 放射性碘活度分类:低1.11 GBq,高3.7 GBq或更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated whether predictive clinicopathologic factors can be affected by different response criteria and how the clinical usefulness of radioactive iodine (RAI) therapy should be evaluated considering variable factors in patients with differentiated thyroid carcinoma (DTC). METHODS: A total of 1563 patients with DTC who underwent first RAI therapy after total or near total thyroidectomy were retrospectively enrolled from 25 hospitals. Response to therapy was evaluated with two different protocols based on combination of biochemical and imaging studies: (1) serum thyroglobulin (Tg) and neck ultrasonography (US) and (2) serum Tg, neck US, and radioiodine scan. The responses to therapy were classified into excellent and non-excellent or acceptable and non-acceptable to minimize the effect of non-specific imaging findings. We investigated which factors were associated with response to therapy depending on the follow-up protocols as well as response classifications. Multivariate logistic regression analysis was performed to identify factors significantly predicting response to therapy. RESULTS: The proportion of patients in the excellent response group significantly decreased from 76.5 to 59.6% when radioiodine scan was added to the follow-up protocol (P < 0.001). Preparation method (recombinant human TSH vs. thyroid hormone withdrawal) was a significant factor for excellent response prediction evaluated with radioiodine scan (OR 2.129; 95% CI 1.687-2.685; P < 0.001) but was not for other types of response classifications. Administered RAI activity, which was classified as low (1.11 GBq) or high (3.7 GBq or higher), significantly predicted both excellent and acceptable responses regardless of the follow-up protocol. CONCLUSIONS: The clinical impact of factors related to response prediction differed depending on the follow-up protocol or classification of response criteria. A high administered activity of RAI was a significant factor predicting a favorable response to therapy regardless of the follow-up protocol or classification of response criteria.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kwon SY, Lee SW, Kong EJ, et al. Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study. Eur J Nucl Med Mol Imaging. 2019. PMID: 31820047. doi:10.1007/s00259-019-04634-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。